Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2024
|
| In: |
Targeted oncology
Year: 2024, Volume: 19, Issue: 5, Pages: 797-809 |
| ISSN: | 1776-260X |
| DOI: | 10.1007/s11523-024-01081-w |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11523-024-01081-w Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s11523-024-01081-w 
|
| Author Notes: | Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1906977976 | ||
| 003 | DE-627 | ||
| 005 | 20241205183200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241028s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-024-01081-w |2 doi | |
| 035 | |a (DE-627)1906977976 | ||
| 035 | |a (DE-599)KXP1906977976 | ||
| 035 | |a (OCoLC)1475327890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michaeli, Daniel |d 1997- |e VerfasserIn |0 (DE-588)1277183244 |0 (DE-627)1830345109 |4 aut | |
| 245 | 1 | 0 | |a Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs |c Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli |
| 264 | 1 | |c September 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 31. Juli 2024 | ||
| 500 | |a Gesehen am 28.10.2024 | ||
| 520 | |a Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination. | ||
| 650 | 4 | |a Drug Development | |
| 700 | 1 | |a Michaeli, Christoph T. |d 1992- |e VerfasserIn |0 (DE-588)1277182337 |0 (DE-627)1830343769 |4 aut | |
| 700 | 1 | |a Albers, Sebastian |d 1991- |e VerfasserIn |0 (DE-588)1258831201 |0 (DE-627)1805362208 |4 aut | |
| 700 | 1 | |a Michaeli, Julia |d 1996- |e VerfasserIn |0 (DE-588)127911424X |0 (DE-627)1832296377 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d Paris : Springer Verlag France S.A.R.L., 2006 |g 19(2024), 5 vom: Sept., Seite 797-809 |h Online-Ressource |w (DE-627)507903838 |w (DE-600)2222136-0 |w (DE-576)284040207 |x 1776-260X |7 nnas |a Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:5 |g month:09 |g pages:797-809 |g extent:13 |a Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11523-024-01081-w |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s11523-024-01081-w |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241028 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1277182337 |a Michaeli, Christoph T. |m 1277182337:Michaeli, Christoph T. |d 60000 |d 61400 |e 60000PM1277182337 |e 61400PM1277182337 |k 0/60000/ |k 1/60000/61400/ |p 2 | ||
| 998 | |g 1277183244 |a Michaeli, Daniel |m 1277183244:Michaeli, Daniel |d 910000 |d 910100 |e 910000PM1277183244 |e 910100PM1277183244 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1906977976 |e 4603000405 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1007/s11523-024-01081-w"],"eki":["1906977976"]},"recId":"1906977976","name":{"displayForm":["Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli"]},"relHost":[{"id":{"eki":["507903838"],"zdb":["2222136-0"],"issn":["1776-260X"]},"recId":"507903838","disp":"Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugsTargeted oncology","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"13","pages":"797-809","volume":"19","text":"19(2024), 5 vom: Sept., Seite 797-809","issue":"5","year":"2024"},"language":["eng"],"title":[{"title_sort":"Targeted oncology","title":"Targeted oncology"}],"pubHistory":["1.2006 -"],"origin":[{"dateIssuedDisp":"2006-","publisher":"Springer Verlag France S.A.R.L.","publisherPlace":"Paris","dateIssuedKey":"2006"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 08.11.2022"]}],"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"language":["eng"],"title":[{"title_sort":"Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs","title":"Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs"}],"person":[{"given":"Daniel","family":"Michaeli","display":"Michaeli, Daniel","role":"aut"},{"role":"aut","display":"Michaeli, Christoph T.","given":"Christoph T.","family":"Michaeli"},{"display":"Albers, Sebastian","given":"Sebastian","family":"Albers","role":"aut"},{"family":"Michaeli","given":"Julia","display":"Michaeli, Julia","role":"aut"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"September 2024"}],"note":["Online veröffentlicht: 31. Juli 2024","Gesehen am 28.10.2024"]} | ||
| SRT | |a MICHAELIDAPATIENTENR2024 | ||